Reteplase biosimilar (Reliance Life Sciences)

瑞替普酶生物类似药 (Reliance Life Sciences)

Report date: 2022/02/18 14:06:03

Base Information

Drug NameReteplase biosimilar (Reliance Life Sciences)

Drug Alias Name瑞替普酶生物仿制药 (Reliance Life Sciences)MiRelR-TPR-004

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionPlasminogen stimulants

TargetsPlasminogen

Therapy Area/IndicationsMyocardial Infarction

Global Approved IndicationsMyocardial Infarction

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2009/01/01

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesReliance Life Sciences

China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences

Inactive CompaniesN/A

Active IndicationsMyocardial Infarction

Inactive IndicationsN/A

Other Information

ATC CodeB01AD07